Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 12/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3593320 | 1.00 | BDKRB1 (0.49) | BDKRB1CYP2D6SMN1; SMN2POLBTDP1 | |
| SCHEMBL5950942 | 0.81 | SMN1; SMN2 (0.47) | BDKRB1CYP2D6SMN1; SMN2POLBTDP1 | |
| SCHEMBL5950940 | 0.81 | SMN1; SMN2 (0.47) | BDKRB1CYP2D6SMN1; SMN2POLBTDP1 | |
| SCHEMBL14064253 | 0.79 | BDKRB1 (0.44) | BDKRB1 | |
| SCHEMBL3533890 | 0.77 | BDKRB1 (0.56) | BDKRB1 | |
| SCHEMBL4138589 | 0.77 | BDKRB1 (0.56) | BDKRB1 | |
| SCHEMBL4816304 | 0.75 | BDKRB1 (0.45) | BDKRB1SMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL3585192 | 0.74 | BDKRB1 (0.49) | BDKRB1 | |
| SCHEMBL3585187 | 0.74 | BDKRB1 (0.49) | BDKRB1 | |
| SCHEMBL13574529 | 0.73 | CYP2D6 (0.71) | CYP2D6SMN1; SMN2POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662811-B2 | N-(((5R)-5-((1-methylethyl)amino)-5,6,7,8-tetrahydro-2-naphthalenyl)methyl)-2-((2R)-1-((4-methylphenyl)sulfonyl)-3-oxo-1,2,3,4-tetrahydro-2-pyrazinyl)acetamide; for treatment of pain and diseases, such as inflammation mediated diseases | AMGEN INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-20060025400-A1 | 1,2,3,4-Tetrahydropyrazin-2-yl acetamides and methods of use | AMGEN INC. | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025400-A1 | 1,2,3,4-Tetrahydropyrazin-2-yl acetamides and methods of use | AADAC, PTGES2, LTC4S | BDKRB1 386/4885CYP2D6 195/4885SMN1; SMN2 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.